The Menarini Group
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From The Menarini Group
The liquid-biopsy test is also a companion diagnostic for osimertinib, AstraZeneca’s drug for non-small cell lung cancer.
The companies expect the Guardant360 CDx liquid-biopsy test to identify patients who will benefit from amivantamab, Janssen’s investigational drug for non-small cell lung cancer.
AACR 2020: Liquid Biopsy Company Guardant Health Presents Colorectal Cancer Data, Outlines Plans For Regulatory Approval
Guardant Health presented new clinical data at this week’s American Association for Cancer Research conference and outlined its growth plans as cancer testing volumes recover after the pandemic.
The company presented positive data from a Phase III pivotal trial during the American Burn Association virtual annual meeting.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Glucose Testing
- Hematology, Coagulation
- Urine-based Testing
- Other Names / Subsidiaries
- A. Menarini Diagnostics S.r.l.
- Berlin Chemie AG
- Invida Group Private Limited
- Menarini Asia-Pacific Holdings (Menarini AP)